MA57574B2 - Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus - Google Patents

Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus

Info

Publication number
MA57574B2
MA57574B2 MA57574A MA57574A MA57574B2 MA 57574 B2 MA57574 B2 MA 57574B2 MA 57574 A MA57574 A MA 57574A MA 57574 A MA57574 A MA 57574A MA 57574 B2 MA57574 B2 MA 57574B2
Authority
MA
Morocco
Prior art keywords
treatment
nucleoside compound
formula
compound represented
negative conversion
Prior art date
Application number
MA57574A
Other languages
English (en)
Other versions
MA57574A1 (fr
Inventor
Junbiao Chang
Jinfa Du
Jiandong Jiang
Yuhuan LI
Original Assignee
Henan Genuine Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Genuine Biotech Co., Ltd. filed Critical Henan Genuine Biotech Co., Ltd.
Publication of MA57574A1 publication Critical patent/MA57574A1/fr
Publication of MA57574B2 publication Critical patent/MA57574B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un composé représenté par la formule (I) ou de ses sels pharmaceutiquement acceptables dans la préparation de médicaments pour prévenir ou traiter les maladies infectieuses à coronavirus. Le composé représenté par la formule (I) est utilisé pour traiter les patients atteints d'une pneumonie causée par un nouveau coronavirus, et présente des avantages évidents en ce qui concerne le rapport de conversion négative du test d'acide nucléique viral, le cours de conversion négative et le temps de guérison et de sortie de l'hôpital.
MA57574A 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus MA57574B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010125799.2A CN113304166B (zh) 2020-02-27 2020-02-27 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
PCT/CN2021/077010 WO2021169861A1 (fr) 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus

Publications (2)

Publication Number Publication Date
MA57574A1 MA57574A1 (fr) 2023-11-30
MA57574B2 true MA57574B2 (fr) 2026-03-31

Family

ID=77370412

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57574A MA57574B2 (fr) 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus

Country Status (15)

Country Link
US (1) US12667583B2 (fr)
EP (1) EP4112050B1 (fr)
JP (1) JP7522845B2 (fr)
KR (1) KR102952809B1 (fr)
CN (2) CN113304166B (fr)
AU (1) AU2021228008B2 (fr)
BR (1) BR112022017209A2 (fr)
CA (1) CA3167927A1 (fr)
IL (1) IL295840B1 (fr)
MA (1) MA57574B2 (fr)
MX (1) MX2022010248A (fr)
NZ (1) NZ791549A (fr)
PH (1) PH12022552236A1 (fr)
WO (1) WO2021169861A1 (fr)
ZA (1) ZA202210636B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113304166B (zh) * 2020-02-27 2022-10-14 河南真实生物科技有限公司 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
EP4319763A4 (fr) * 2021-04-09 2025-06-11 Emory University Analogues de nucléosides et de nucléotides modifiés utilisés en tant qu'agents antiviraux contre le coronavirus et d'autres virus
CN114288313B (zh) * 2022-02-18 2023-07-04 常晓宇 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途
CN118021821A (zh) * 2022-03-03 2024-05-14 苏州旺山旺水生物医药股份有限公司 治疗、预防由病毒感染引起的相关疾病的药物及其用途
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法
CN117982522A (zh) * 2022-11-02 2024-05-07 河南真实生物科技有限公司 核苷类化合物的制药用途
WO2024103016A1 (fr) * 2022-11-11 2024-05-16 Rome Therapeutics, Inc. 4'-halométhyl-cytidine phosphoramidates et composés apparentés et leur utilisation dans le traitement d'affections médicales
CN121891392A (zh) * 2024-10-18 2026-04-21 河南真实生物科技有限公司 阿兹夫定类药物的制药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018030A1 (fr) * 2001-08-24 2003-03-06 Koronis Pharmaceuticals, Inc. Analogues de nucleoside mutagene pour le traitement d'une maladie virale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
CN100398555C (zh) * 2003-05-06 2008-07-02 西托维亚公司 冠状病毒和sars-cov的蛋白酶抑制剂及其应用
WO2005020885A2 (fr) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions et methodes pour le traitement du syndrome respiratoire aigu severe (sras)
CN1237185C (zh) * 2003-06-04 2006-01-18 中国科学院上海药物研究所 Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
US10434116B2 (en) * 2014-04-07 2019-10-08 University Of Maryland, Baltimore Methods of treating coronavirus infection
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2019123338A1 (fr) * 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. Dinucléotides 2'2' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting
WO2019161017A1 (fr) * 2018-02-15 2019-08-22 Gilead Sciences, Inc. Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih
CN109893536B (zh) 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
TWI829205B (zh) * 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
CN113304166B (zh) * 2020-02-27 2022-10-14 河南真实生物科技有限公司 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018030A1 (fr) * 2001-08-24 2003-03-06 Koronis Pharmaceuticals, Inc. Analogues de nucleoside mutagene pour le traitement d'une maladie virale

Also Published As

Publication number Publication date
MA57574A1 (fr) 2023-11-30
AU2021228008A1 (en) 2022-09-22
EP4112050A1 (fr) 2023-01-04
EP4112050A4 (fr) 2024-03-20
CN116098917A (zh) 2023-05-12
AU2021228008B2 (en) 2024-08-08
CN113304166A (zh) 2021-08-27
CA3167927A1 (fr) 2021-09-02
KR102952809B1 (ko) 2026-04-15
US20230277576A1 (en) 2023-09-07
US12667583B2 (en) 2026-06-30
JP7522845B2 (ja) 2024-07-25
BR112022017209A2 (pt) 2022-10-11
NZ791549A (en) 2026-03-27
ZA202210636B (en) 2024-01-31
PH12022552236A1 (en) 2024-02-05
KR20220146496A (ko) 2022-11-01
IL295840B1 (en) 2026-07-01
EP4112050B1 (fr) 2026-05-06
EP4112050C0 (fr) 2026-05-06
CN113304166B (zh) 2022-10-14
JP2023516628A (ja) 2023-04-20
MX2022010248A (es) 2022-10-10
WO2021169861A1 (fr) 2021-09-02
IL295840A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
ZA202210636B (en) Use of nucleoside compound in treatment of coronavirus infectious diseases
MA56074B1 (fr) Anticorps contre le sars-cov-2
Hamidi-Alamdari et al. Methylene blue for treatment of hospitalized covid-19 patients: a randomized, controlled, open-label clinical trial, phase 2
UY25869A1 (es) Moduladores de ccr5, formulaciones farmacéuticas, procedimientos y sus usos.
Field et al. Antibiotic treatment of epidemic bronchiolitis--a double-blind trial
MX2021010834A (es) Compuesto y metodo para la prevencion de transmision del virus de influenza.
Fulcher et al. Emergence of integrase resistance mutations during initial therapy with TDF/FTC/DTG
Parsons et al. Inoculation of human volunteers with strains of Coe virus isolated in Britain
Adkins et al. Esophageal perforation in a patient with acquired immunodeficiency syndrome
GEP20227432B (en) Therapy of high-risk human papillomavirus infections
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
RU94038588A (ru) Способ лечения вторичного иммунодефицита (вид)
MONTGOMERy et al. Erythromycin in treatment of early syphilis
EP4132518A1 (fr) Méthodes de traitement d'infections à sras-cov-2
MX2022012487A (es) Métodos para tratar y/o prevenir infecciones y/o enfermedades virales causadas por virus en un sujeto que lo necesita.
WO2021251792A1 (fr) Composition pharmaceutique pour le traitement du syndrome respiratoire covid-19
Marchenko et al. ADVANTAGES OF BUSINESS GAME METHOD IN TEACHING DISCIPLINE" INFECTIOUS DISEASES" TO FUTURE DENTAL DOCTORS
Hwang et al. Benign Anal Diseases on Patients with HIV Disease.
US20230149364A1 (en) Methods of treating viral infections
Cornish Respiratory depression with addition of fentanyl to spinal anesthesia
Fauci An interview with Anthony S. Fauci, MD. Interview by Mark Mascolini
Ebert et al. The results of intensive treatment of patients with chronic bronchitis and pulmonary emphysema
RU2234919C2 (ru) Способ консервативной остановки легочных кровотечений
UA126256U (uk) Спосіб лікування вірусного гепатиту в у дітей
EA200700170A1 (ru) Применение фенилэтаноламинотетралинов для приготовления анксиолитических лекарственных препаратов